Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Aug;111(10):1326–1334. doi: 10.1289/ehp.111-1241614

Neurologic outcomes of toxic oil syndrome patients 18 years after the epidemic.

Manuel Posada de la Paz 1, Rossanne M Philen 1, Fredric Gerr 1, Richard Letz 1, Maria José Ferrari Arroyo 1, Lydia Vela 1, Maravillas Izquierdo 1, Concepción Martín Arribas 1, Ignacio Abaitua Borda 1, Alejandro Ramos 1, Cristina Mora 1, Gloria Matesanz 1, Maria Teresa Roldán 1, Juan Pareja 1
PMCID: PMC1241614  PMID: 12896854

Abstract

Toxic oil syndrome (TOS) resulted from consumption of rapeseed oil denatured with 2% aniline and affected more than 20,000 persons. Eighteen years after the epidemic, many patients continue to report neurologic symptoms that are difficult to evaluate using conventional techniques. We conducted an epidemiologic study to determine whether an exposure to toxic oil 18 years ago was associated with current adverse neurobehavioral effects. We studied a case group of 80 adults exposed to toxic oil 18 years ago and a referent group of 79 adult age- and sex-frequency-matched unexposed subjects. We interviewed subjects for demographics, health status, exposures to neurotoxicants, and responses to the Kaufman Brief Intelligence Test (K-BIT), Programa Integrado de Exploracion Neuropsicologica (PIEN), and Goldberg depression questionnaires and administered quantitative neurobehavioral and neurophysiologic tests by computer or trained nurses. The groups did not differ with respect to educational background or other critical variables. We examined associations between case and referent groups and the neurobehavioral and neurophysiologic outcomes of interest. Decreased distal strength of the dominant and nondominant hands and increased vibrotactile thresholds of the fingers and toes were significantly associated with exposure to toxic oil. Finger tapping, simple reaction time latency, sequence B latency, symbol digit latency, and auditory digit span were also significantly associated with exposure. Case subjects also had statistically significantly more neuropsychologic symptoms compared with referents. Using quantitative neurologic tests, we found significant adverse central and peripheral neurologic effects in a group of TOS patients 18 years after exposure to toxic oil when compared with a nonexposed referent group. These effects were not documented by standard clinical examination and were found more frequently in women.

Full Text

The Full Text of this article is available as a PDF (170.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abaitua Borda I., Philen R. M., Posada de la Paz M., Gómez de la Cámara A., Díez Ruiz-Navarro M., Giménez Ribota O., Alvargonzález Soldevilla J., Terracini B., Severiano Peña S., Fuentes Leal C. Toxic oil syndrome mortality: the first 13 years. Int J Epidemiol. 1998 Dec;27(6):1057–1063. doi: 10.1093/ije/27.6.1057. [DOI] [PubMed] [Google Scholar]
  2. Baker E. L., Letz R. E., Eisen E. A., Pothier L. J., Plantamura D. L., Larson M., Wolford R. Neurobehavioral effects of solvents in construction painters. J Occup Med. 1988 Feb;30(2):116–123. [PubMed] [Google Scholar]
  3. Baker E. L., Letz R., Fidler A. A computer-administered neurobehavioral evaluation system for occupational and environmental epidemiology. Rationale, methodology, and pilot study results. J Occup Med. 1985 Mar;27(3):206–212. [PubMed] [Google Scholar]
  4. Gelpí Emilio, de la Paz Manuel Posada, Terracini Benedetto, Abaitua Ignacio, de la Cámara Agustín Gómez, Kilbourne Edwin M., Lahoz Carlos, Nemery Bénoit, Philen Rossanne M., Soldevilla Luis. The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge. Environ Health Perspect. 2002 May;110(5):457–464. doi: 10.1289/ehp.110-1240833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gerr F. E., Letz R. Reliability of a widely used test of peripheral cutaneous vibration sensitivity and a comparison of two testing protocols. Br J Ind Med. 1988 Sep;45(9):635–639. doi: 10.1136/oem.45.9.635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gerr F., Hershman D., Letz R. Vibrotactile threshold measurement for detecting neurotoxicity: reliability and determination of age- and height-standardized normative values. Arch Environ Health. 1990 May-Jun;45(3):148–154. doi: 10.1080/00039896.1990.9936708. [DOI] [PubMed] [Google Scholar]
  7. Gerr F., Letz R., Hershman D., Farraye J., Simpson D. Comparison of vibrotactile thresholds with physical examination and electrophysiological assessment. Muscle Nerve. 1991 Nov;14(11):1059–1066. doi: 10.1002/mus.880141104. [DOI] [PubMed] [Google Scholar]
  8. Gómez de la Cámara A., Posada de la Paz M., Abaitua Borda I., Barainca Oyagüe M. T., Abraira Santos V., Ruiz-Navarro M. D., Terracini B. Health status measurement in Toxic Oil Syndrome. J Clin Epidemiol. 1998 Oct;51(10):867–873. doi: 10.1016/s0895-4356(98)00062-6. [DOI] [PubMed] [Google Scholar]
  9. Kilbourne E. M. Eosinophilia-myalgia syndrome: coming to grips with a new illness. Epidemiol Rev. 1992;14:16–36. doi: 10.1093/oxfordjournals.epirev.a036085. [DOI] [PubMed] [Google Scholar]
  10. Kilbourne E. M., Posada de la Paz M., Abaitua Borda I. Epidemiological studies. WHO Reg Publ Eur Ser. 1992;42:5–25. [PubMed] [Google Scholar]
  11. Letz R., Gerr F. Standing steadiness measurements: empirical selection of testing protocol and outcome measures. Neurotoxicol Teratol. 1995 Nov-Dec;17(6):611–616. doi: 10.1016/0892-0362(95)00023-2. [DOI] [PubMed] [Google Scholar]
  12. Letz R., Green R. C., Woodard J. L. Development of a computer-based battery designed to screen adults for neuropsychological impairment. Neurotoxicol Teratol. 1996 Jul-Aug;18(4):365–370. doi: 10.1016/0892-0362(96)00041-4. [DOI] [PubMed] [Google Scholar]
  13. Letz R. Use of computerized test batteries for quantifying neurobehavioral outcomes. Environ Health Perspect. 1991 Jan;90:195–198. doi: 10.1289/ehp.90-1519520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Martín Alvarez H., Plaza Cano M., Estirado de Cabo E., García de Aguinaga M., Izquierdo Martínez M., Posada de la Paz M. Hallazgos clínicos y analíticos en pacientes afectados por el síndrome del aceite tóxico. Estudio de una cohorte de 758 pacientes. Rev Clin Esp. 2000 Jun;200(6):305–309. doi: 10.1016/s0014-2565(00)70642-4. [DOI] [PubMed] [Google Scholar]
  15. Mathiowetz V., Weber K., Volland G., Kashman N. Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am. 1984 Mar;9(2):222–226. doi: 10.1016/s0363-5023(84)80146-x. [DOI] [PubMed] [Google Scholar]
  16. Montón C., Pérez Echeverría M. J., Campos R., García Campayo J., Lobo A. Escalas de ansiedad y depresión de Goldberg: una guía de entrevista eficaz para la detección del malestar psíquico. Aten Primaria. 1993 Oct 15;12(6):345–349. [PubMed] [Google Scholar]
  17. Philen R. M., Posada M. Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report. Semin Arthritis Rheum. 1993 Oct;23(2):104–124. doi: 10.1016/s0049-0172(05)80017-4. [DOI] [PubMed] [Google Scholar]
  18. Posada de la Paz M., Abaitua I., Terracini B., Giménez O., Sánchez-Porro P., Gómez-Mera C. Late deaths among young women affected by the toxic oil syndrome in Spain. Epidemiology. 1999 May;10(3):345–345. doi: 10.1097/00001648-199905000-00026. [DOI] [PubMed] [Google Scholar]
  19. Posada de la Paz M., Philen R. M., Borda A. I. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev. 2001;23(2):231–247. doi: 10.1093/oxfordjournals.epirev.a000804. [DOI] [PubMed] [Google Scholar]
  20. Ricoy J. R., Cabello A., Rodriguez J., Téllez I. Neuropathological studies on the toxic syndrome related to adulterated rapeseed oil in Spain. Brain. 1983 Dec;106(Pt 4):817–835. doi: 10.1093/brain/106.4.817. [DOI] [PubMed] [Google Scholar]
  21. Stokes L., Letz R., Gerr F., Kolczak M., McNeill F. E., Chettle D. R., Kaye W. E. Neurotoxicity in young adults 20 years after childhood exposure to lead: the Bunker Hill experience. Occup Environ Med. 1998 Aug;55(8):507–516. doi: 10.1136/oem.55.8.507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sullivan E. A., Kamb M. L., Jones J. L., Meyer P., Philen R. M., Falk H., Sinks T. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina. Arch Intern Med. 1996 May 13;156(9):973–979. [PubMed] [Google Scholar]
  23. Tabuenca J. M. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet. 1981 Sep 12;2(8246):567–568. doi: 10.1016/s0140-6736(81)90949-1. [DOI] [PubMed] [Google Scholar]
  24. Tyler Kenneth L. Creutzfeldt-Jakob disease. N Engl J Med. 2003 Feb 20;348(8):681–682. doi: 10.1056/NEJMp020187. [DOI] [PubMed] [Google Scholar]
  25. van Larebeke N., Hens L., Schepens P., Covaci A., Baeyens J., Everaert K., Bernheim J. L., Vlietinck R., De Poorter G. The Belgian PCB and dioxin incident of January-June 1999: exposure data and potential impact on health. Environ Health Perspect. 2001 Mar;109(3):265–273. doi: 10.1289/ehp.01109265. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of American Chemical Society

RESOURCES